The 16p11.2 duplication is a copy number variant that has been previously identified to confer risk for diverse neuropsychiatric disorders, including autism spectrum disorder, schizophrenia, intellectual disability and epilepsy. Researchers from Northwestern University Feinberg School of Medicine aimed to assess disease networks associated with this broad phenotypic spectrum.
Estrella Biopharma Inc. has received FDA clearance of its IND application for lead product candidate EB-103, a T-cell therapy targeting CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas.
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, which lacks effective targeted therapies. Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib are the go-to therapeutic strategy, but are often tied to resistance.
Modex Therapeutics Inc., an Opko Health Inc. company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co. Inc., for the development of MDX-2201, Modex's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV).
Since abnormal choline accumulation in cancer cells has been strongly correlated with malignant tumor growth, researchers from Tokyo Medical University aimed to analyze the functional expression of choline transporters in human hepatocellular carcinoma (HCC).
Head and neck squamous cell carcinoma (HNSCC) develops in the epithelial lining of the oral cavity, hypopharynx, oropharynx or larynx. The standard treatment includes platinum-based and taxane-based chemotherapy that causes both drug resistance and negative side effects.For that reason, there is a need to explore new low-toxicity options for HNSCC treatment.
Scientists from Washington University in St. Louis have described a role for T cells in the neurodegeneration associated with the tau protein. Tau accumulation in the brain activated microglia. This signal triggered the activation of T cells in other parts of the body, attracting them to the brain. Once there, the interaction of these T cells and microglia produced the neuronal damage seen in Alzheimer’s disease and other tauopathies.
The U.S. Recover program, set up in July 2022 to identify the causes of long COVID, find biomarkers of disease and discover new therapeutic targets, is now preparing to move to its next phase and begin testing potential treatments in a multi-arm, randomized, placebo-controlled trial. But with 200 different symptoms, and limited understanding of relevant system-level pathological targets, there are significant hurdles to be overcome.
Massachusetts General Hospital and University of California Oakland have described 15-lipoxygenase (LOX) inhibitors reported to be useful for the treatment of stroke, among others.
RSS
